CPRX Stock Catalyst Pharmaceuticals (CPRX, $20.23) Stochastic Oscillator left the oversold zone on August 15, 2025

GET DAILY SIGNALS

Get AI intraday signals

CPRX - Catalyst Pharmaceuticals

Stochastic signal

View

Odds of UP Trend

Price: $20.23

Daily change: +$0.16 (+0.8%)

Daily volume: 2M

Capitalization: $2.5B

Industry: Biotechnology

CPRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on August 07, 2025

CPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 27 cases where CPRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CPRX advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CPRX as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CPRX turned negative on August 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CPRX entered a downward trend on July 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.893) is normal, around the industry mean (19.528). P/E Ratio (12.261) is within average values for comparable stocks, (52.377). CPRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.945). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (4.585) is also within normal values, averaging (294.394).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CPRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.